Comprehensive Characterization of Difficult-to-Treat Asthma Reveals Near Absence of T2-Low Status-Reference-Cited by-同舟云学术

Comprehensive Characterization of Difficult-to-Treat Asthma Reveals Near Absence of T2-Low Status

Published:2023-09 Issue:9 Volume:11 Page:2812-2821.e4
ISSN:2213-2198
Container-title:The Journal of Allergy and Clinical Immunology: In Practice
language:en
Short-container-title:The Journal of Allergy and Clinical Immunology: In Practice

Author:

Rupani Hitasha,Kyyaly Mohammed Aref,Azim Adnan,Abadalkareen Rana,Freeman Anna,Dennison Paddy,Howarth Peter,Djukanovic Ratko,Vijayanand Pandurangan,Seumois Gregory,Arshad S. Hasan,Haitchi Hans Michael,Kurukulaaratchy Ramesh J.

Publisher

Elsevier BV

Subject

Immunology and Allergy

Reference24 articles.

1. T2-“low” asthma: overview and management strategies;Fitzpatrick;J Allergy Clin Immunol Pract,2020

2. Treatment options in type-2 low asthma;Hinks;Eur Respir J,2021

3. Real-world omalizumab and mepolizumab treated difficult asthma phenotypes and their clinical outcomes;Fong;Clin Exp Allergy,2021

4. Biologic therapies for severe asthma;Brusselle;N Engl J Med,2022

5. Severe and difficult-to-treat asthma in adults;Israel;N Engl J Med,2017

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype;New England Journal of Medicine;2024-09-09

2. Body Weight and Allergic Asthma: A Narrative Review;Journal of Clinical Medicine;2024-08-15

3. Endotyping Chronic Respiratory Diseases: T2 Inflammation in the United Airways Model;Life;2024-07-19

4. Decreased FEF50 as an indicator of comorbid asthma and persistent airflow limitation in patients with chronic rhinosinusitis with nasal polyps: A cross-sectional study;Chinese Medical Journal;2024-01-11

5. Effects of biological therapies on patients with Type-2 high asthma and comorbid obesity;Frontiers in Pharmacology;2024-01-08